Development of VEGFR2-specific nanobody Pseudomonas exotoxinA conjugated to provide efficient inhibition of tumour cell growth.

Mahdi Behdani, Sirous Zeinali, Morteza Karimipour, Hossein Khanahmad, Steve Schoonooghe, Azam Aslemarz, Negar Seyed, Reza Moazami-Godarzi, Farzad Baniahmad, Mahdi Habibi Anbouhi, Gholamreza Hassanzadeh Ghassabeh, Serge Muyldermans

Onderzoeksoutput: Article

61 Citaten (Scopus)

Samenvatting

Angiogenesis targeting is an attractive approach for cancer treatment. Vascular endothelial growth
factor receptor 2 (VEGFR2) is such an important target that is overexpressed in tumor vasculature
compared to the endothelium cells of resting blood vessels and blocking of its signaling inhibits
neovascularization and tumor metastasis. Immunotoxins represent a promising group of targeted
therapeutics to combat tumors. They consist of an antibody linked to a toxin and are designed to kill
specifically the tumor cells. In this study, we fused a VEGFR2-specific Nanobody, the antigen-binding
single-domain fragment derived from functional Heavy-chain antibody of Camelidae, to the truncated
form of Pseudomonas exotoxin A and evaluated its ability to bind the VEGFR2 molecule on the cell
surface. We demonstrate that this immunotoxin inhibits the proliferation of VEGFR2-expressing cells in
vitro. This finding is considered to be a significant achievement in tumor therapy and it forms a basis for
further studies in animal models.
Originele taal-2English
Pagina's (van-tot)205-209
Aantal pagina's5
TijdschriftNew Biotechnology
Volume30
StatusPublished - 2013

Vingerafdruk

Duik in de onderzoeksthema's van 'Development of VEGFR2-specific nanobody Pseudomonas exotoxinA conjugated to provide efficient inhibition of tumour cell growth.'. Samen vormen ze een unieke vingerafdruk.

Citeer dit